Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.

Song C, Gao Y, Tian Y, Han X, Chen Y, Tian DL.

Tumour Biol. 2013 Jun;34(3):1925-33. doi: 10.1007/s13277-013-0737-8. Epub 2013 Mar 20.

PMID:
23512329
2.

High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.

Wei LX, Zhou RS, Xu HF, Wang JY, Yuan MH.

Tumour Biol. 2013 Apr;34(2):941-6. doi: 10.1007/s13277-012-0629-3. Epub 2012 Dec 22.

PMID:
23264086
3.

Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.

Han KY, Gu X, Wang HR, Liu D, Lv FZ, Li JN.

Tumour Biol. 2013 Apr;34(2):821-5. doi: 10.1007/s13277-012-0612-z. Epub 2012 Dec 11.

PMID:
23229099
4.

GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.

Zhang Y, Ma M, Han B.

Tumour Biol. 2014 Nov;35(11):10833-9. doi: 10.1007/s13277-014-2357-3. Epub 2014 Aug 1.

PMID:
25081375
5.

Prognostic significance of TAZ expression in resected non-small cell lung cancer.

Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY.

J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b.

6.

TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis.

Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM, Lei B, Sheng WJ, Shen H.

Asian Pac J Cancer Prev. 2014;15(19):8143-7.

7.

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.

Ni SS, Zhang J, Zhao WL, Dong XC, Wang JL.

Tumour Biol. 2013 Jun;34(3):1813-8. doi: 10.1007/s13277-013-0721-3. Epub 2013 Mar 9.

PMID:
23475633
8.

Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.

Ping W, Jiang WY, Chen WS, Sun W, Fu XN.

Asian Pac J Cancer Prev. 2013;14(6):3613-8.

9.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

10.

Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.

Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D, Shan L.

Med Oncol. 2014 May;31(5):963. doi: 10.1007/s12032-014-0963-y. Epub 2014 Apr 20.

PMID:
24748406
11.

mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.

Wang L, Yue W, Zhang L, Zhao X, Wang Y, Xu S.

Surg Today. 2012 May;42(5):419-25. doi: 10.1007/s00595-011-0028-1. Epub 2011 Nov 30.

PMID:
22127531
12.

Prognostic significance of annexin II expression in non-small cell lung cancer.

Luo CH, Liu QQ, Zhang PF, Li MY, Chen ZC, Liu YF.

Clin Transl Oncol. 2013 Nov;15(11):938-46. doi: 10.1007/s12094-013-1028-y. Epub 2013 Mar 26.

PMID:
23529818
13.

HSP90B1 overexpression predicts poor prognosis in NSCLC patients.

Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Wang X, Wang W, Chai F, Li X.

Tumour Biol. 2016 Oct;37(10):14321-14328. Epub 2016 Sep 6.

PMID:
27599983
14.

Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.

Jacobsen B, Muley T, Meister M, Dienemann H, Christensen IJ, Santoni-Rugiu E, Lærum OD, Ploug M.

J Thorac Oncol. 2013 Feb;8(2):152-60. doi: 10.1097/JTO.0b013e318279d503.

15.

An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.

Wei K, Ye Z, Li Z, Dang Y, Chen X, Huang N, Bao C, Gan T, Yang L, Chen G.

World J Surg Oncol. 2016 Feb 9;14(1):34. doi: 10.1186/s12957-016-0787-7.

16.

The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.

Le H, Zeng F, Xu L, Liu X, Huang Y.

Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.

PMID:
24008862
17.

Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.

Lin G, Sun L, Wang R, Guo Y, Xie C.

J Thorac Oncol. 2014 Feb;9(2):170-8. doi: 10.1097/JTO.0000000000000066.

18.

Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Li H, Zhou RJ, Zhang GQ, Xu JP.

Tumour Biol. 2013 Jun;34(3):1807-12. doi: 10.1007/s13277-013-0720-4. Epub 2013 Mar 8.

PMID:
23471668
19.

Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.

Zhang H, Duan CJ, Chen W, Wang SQ, Zhang SK, Dong S, Cheng YD, Zhang CF.

Asian Pac J Cancer Prev. 2012;13(5):2355-62.

Supplemental Content

Support Center